Regencell Bioscience (RGC) stock slides nearly 5% in year-end trading as volatility persists
31 December 2025
1 min read

Regencell Bioscience (RGC) stock slides nearly 5% in year-end trading as volatility persists

NEW YORK, December 31, 2025, 11:51 ET — Regular session

  • Regencell Bioscience Holdings (RGC) fell about 5% in late morning trade, after another two-day stretch of sharp swings.
  • With no fresh company news, traders focused on thin year-end liquidity and the stock’s wide trading ranges.

Regencell Bioscience Holdings Limited shares were down 4.8% at $21.79 as of 11:51 a.m. ET, after trading between $21.44 and $23.11 in a choppy session.

The move came without any new company announcements. Regencell’s investor-relations site lists its most recent press release dated Oct. 31, and the latest SEC filing on EDGAR is its annual report filed the same day. 1

The pullback also tracked a softer tape across Wall Street on the final trading day of 2025, with trading volumes muted heading into the New Year’s holiday. “Describing 2025 as ‘resilient’ might be an understatement,” said Adam Turnquist, chief technical strategist at LPL Financial. 2

Regencell has been prone to fast moves. The stock ended Tuesday at $22.90 after ranging from $22.17 to $25.30, with 394,200 shares traded, according to historical data. 3

On Monday, shares opened sharply lower before reversing, MarketBeat reported, underscoring how quickly price action can flip in the name. 4

Regencell is a bioscience company focused on research and development of traditional Chinese medicine (TCM) candidates aimed at neurocognitive disorders including ADHD and autism spectrum disorder, according to its company profile. 5

The company has also faced heightened investor scrutiny after disclosing a U.S. Department of Justice subpoena. In its annual report, Regencell said it received correspondence and a subpoena from the DOJ indicating it was investigating trading in the company’s ordinary shares. 6

With no new disclosures since that filing, traders have leaned heavily on price action. By late morning, just over 60,000 shares had changed hands, a pace below Tuesday’s turnover.

That can matter in a stock that has shown wide intraday bands. Thin volumes can exaggerate swings when orders hit the market in clusters.

Technicians often watch “support” and “resistance” levels — areas where buying or selling has tended to show up in the past. For Regencell, traders are eyeing the $21.44 low as a near-term floor and $23.11 as the first hurdle, with last session’s $25.30 high sitting above that.

What investors are watching next is straightforward: any new SEC filing, any company comment tied to the DOJ matter, and whether volume returns after the New Year’s break.

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus
Previous Story

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Broadcom stock slips today as insider sale filings hit tape in thin year-end trade
Next Story

Broadcom stock slips today as insider sale filings hit tape in thin year-end trade

Go toTop